News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Evidence also shows better immune response to virus among users of spray
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Shaan’s hit song `Tanha Dil Tanha Safar relaunched
The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence
Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.
The process is completed with the help of a balloon at a low temperature so that other cells are undamaged and the patient can return home the next day
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Subscribe To Our Newsletter & Stay Updated
